Market Overview

UPDATE: Credit Suisse Initiates PennyMac Financial Services at Neutral on Attractive Growth Platform


In a report published Monday, Credit Suisse analyst Douglas Harter initiated coverage on PennyMac Financial Services (NYSE: PFSI) with a Neutral rating and $24.00 price target.

In the report, Credit Suisse noted, “We are initiating coverage of PFSI with a Neutral rating and a $24 target price. We view PFSI as a leading platform in the nonbank servicing and origination sector. However, we currently see better value in our Outperform-rated servicers, NSM and WAC. We expect PFSI to grow its servicing portfolio to $284 billion by the end of 2015. This growth is primarily being driven by the growing originations volume and supplemented by acquisitions of MSRs. The growth of the servicing portfolio is a key driver of the expected growth of the retail originations channel through the recapture of refinanced loans. Gain-on-sale margins have continued to decline in the second quarter, albeit at a more moderate rate than in the first quarter. We expect GOS margins to continue to decline over the coming quarters as the market normalizes.”

PennyMac Financial Services closed on Friday at $21.95.

Latest Ratings for PFSI

Sep 2019MaintainsOverweight
Sep 2019UpgradesMarket PerformOutperform
Aug 2019MaintainsNeutral

View More Analyst Ratings for PFSI
View the Latest Analyst Ratings

Posted-In: Credit Suisse Douglas HarterAnalyst Color Initiation Analyst Ratings


Related Articles (PFSI)

View Comments and Join the Discussion!

Latest Ratings

PTONBank of AmericaInitiates Coverage On29.0
ITRICanaccord GenuityMaintains87.0
GWPHNeedhamInitiates Coverage On200.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: Credit Suisse Initiates Receptos at Outperform on R&D Focus

Novartis Says Breakthrough Therapy LDK378 Shows Marked Clinical Response